Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

医学 催眠药 福尔菲里 贝伐单抗 内科学 安慰剂 肿瘤科 二线疗法 结直肠癌 奥沙利铂 癌症 总体生存率 化疗 病理 替代医学
作者
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannová,G. Bodoky,Rocio García‐Carbonero,Tudor‐Eliade Ciuleanu,David C. Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García‐Alfonso,Kentaro Yamazaki,Philip R. Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao-Chun Chang,Federico Nasroulah
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (5): 499-508 被引量:866
标识
DOI:10.1016/s1470-2045(15)70127-0
摘要

Background Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF receptor 2. We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Methods Between Dec 14, 2010, and Aug 23, 2013, we enrolled patients into the multicentre, randomised, double-blind, phase 3 RAISE trial. Eligible patients had disease progression during or within 6 months of the last dose of first-line therapy. Patients were randomised (1:1) via a centralised, interactive voice-response system to receive 8 mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until disease progression, unacceptable toxic effects, or death. Randomisation was stratified by region, KRAS mutation status, and time to disease progression after starting first-line treatment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01183780.ld Findings We enrolled 1072 patients (536 in each group). Median overall survival was 13·3 months (95% CI 12·4–14·5) for patients in the ramucirumab group versus 11·7 months (10·8–12·7) for the placebo group (hazard ratio 0·844 95% CI 0·730–0·976; log-rank p=0·0219). Survival benefit was consistent across subgroups of patients who received ramucirumab plus FOLFIRI. Grade 3 or worse adverse events seen in more than 5% of patients were neutropenia (203 [38%] of 529 patients in the ramucirumab group vs 123 [23%] of 528 in the placebo group, with febrile neutropenia incidence of 18 [3%] vs 13 [2%]), hypertension (59 [11%] vs 15 [3%]), diarrhoea (57 [11%] vs 51 [10%]), and fatigue (61 [12%] vs 41 [8%]). Interpretation Ramucirumab plus FOLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma. No unexpected adverse events were identified and toxic effects were manageable. Funding Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jason完成签到,获得积分10
刚刚
刚刚
歪比巴卜完成签到,获得积分10
1秒前
卿卿完成签到,获得积分20
2秒前
云墨完成签到 ,获得积分10
2秒前
SilentStorm完成签到,获得积分10
2秒前
3秒前
4秒前
sunnyfriend完成签到,获得积分10
4秒前
xiaozang完成签到,获得积分10
5秒前
怕黑寻雪完成签到 ,获得积分10
5秒前
6秒前
李白完成签到,获得积分10
7秒前
正直涵菱发布了新的文献求助10
7秒前
感性的酬海完成签到,获得积分10
8秒前
王王的狗子完成签到 ,获得积分10
8秒前
innyjiang完成签到,获得积分10
10秒前
陆王牛马完成签到 ,获得积分10
11秒前
11秒前
Ava应助念念采纳,获得10
12秒前
LIAO完成签到,获得积分10
12秒前
迅速凝竹完成签到 ,获得积分10
14秒前
妮妮完成签到,获得积分10
15秒前
15秒前
哈哈哈完成签到,获得积分20
16秒前
快乐随心完成签到 ,获得积分10
17秒前
了一李完成签到 ,获得积分10
17秒前
fqk完成签到,获得积分10
17秒前
活泼新儿完成签到,获得积分10
17秒前
18秒前
老迟到的羊完成签到 ,获得积分10
18秒前
可爱的函函应助sl采纳,获得30
22秒前
CatC完成签到,获得积分10
22秒前
LIKO完成签到,获得积分10
22秒前
22秒前
22秒前
David发布了新的文献求助10
23秒前
23秒前
clock完成签到 ,获得积分10
23秒前
风中小懒虫完成签到,获得积分10
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029